Alliance for Balanced Pain Management launches

The Alliance for Balanced Pain Management (AfBPM) has been established by a diverse collective of 22 advocacy groups representing health care advocacy organizations, patient organizations, industry representatives, and others.  AfBPM supports appropriate access to integrated pain management and responsible use of prescription pain medicines with an aim to reduce abuse.  The alliance will work collaboratively […]

Pain specialists show increasing burnout, prevention programs needed

Pain specialists are at increased risk for burnout, and thus at increased risk for substance abuse, interpersonal difficulties, suicidal tendencies, according to a recent study.  What’s more, burnout can have a direct effect on patients, as clinicians experiencing burnout are at increased risk for causing medical errors.  To counteract this tendency toward burnout, study investigators […]

FDA approves abuse-deterrent hydrocodone Hysingla

The U.S. Food and Drug Administration (FDA) has approved a second hydrocodone-only opioid pain reliever; however, the new drug, Hysingla, has abuse-deterrent properties consistent with FDA guidance on the topic.  According to the FDA, the pill is difficult to crush, break, or dissolve, and when it placed in water it forms a viscous hydrogel that […]

Revisions to pain management standard effective January 1, 2015

The Joint Commission, a not-for-profit organization that accredits and certifies more than 20,500 health care organizations and programs in the United States, has released revisions affecting pain management in ambulatory care, critical access hospital, home care, hospital, nursing care center, and office-based surgery accreditation programs.  The newly updated standard affirmed that treatment strategies may consider […]

Pain patients forced to go ‘cold turkey’ from hydrocodone

In early October, in an effort to combat a nationwide “epidemic” of prescription drug abuse, hydrocodone combination products were rescheduled by the DEA from Schedule III to the more restrictive Schedule II.  The rescheduling limits patients to an initial 90-day supply and requires them to see a doctor for a new prescription each time they […]